Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$44.03 USD
-0.08 (-0.18%)
Updated May 17, 2024 03:59 PM ET
After-Market: $44.04 +0.01 (0.02%) 6:40 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BMY 44.03 -0.08(-0.18%)
Will BMY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Walmart Earnings & the State of the Consumer
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Other News for BMY
Bristol-Myers publishes data on Sotyktu,CheckMate; gets FDA approval
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
May's 5 Dividend Growth Stocks With 5.49%+ Yields
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
Hold Rating on Bristol-Myers Squibb Amid Mounting Competition and Flat Growth Projections